source
- Reverse mergers surge as biotech firms seek public listings via shell companiesReverse mergers, once dismissed, are now a common route for biotech startups to gain a public listing by merging with shell companies. Data from JB Strategy Partners shows roughly two dozen such d…
- Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successesAndy Plump, M.D., Ph.D., president of research and development at Takeda, is set to leave the company in June.Fierce Biotech · 5h ago↗ source